AgingResearch.NewsJoin free

Eidos Therapeutics

Part of BridgeBio

CompanyUnited States

Eidos Therapeutics develops one asset, approved (Acoramidis). Mostly small molecule acting on TTR; based in the United States.

1
Asset
Furthest stage
Approved
Raised
$170M
3
Trials
2
Signals

Pipeline

1

  • Acoramidis

    Kinetic stabilizer of transthyretin tetramers preventing amyloidogenesis and fibril accumulation

    Approved, Small molecule, TTR, cardiac amyloidosis (Phase 3), amyloid (Phase 3)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials3
  • Funding rounds and grants2
  • Signals5
  • Similar companies6

Intelligence